FDA Adds Raptiva Black Box Warning About Serious Infections
The FDA is adding a new “black box” warning to the psoriasis drug Raptiva. Side effects could include an increased risk of potentially life-threatening infections, including the brain disease progressive multifocal leukoencephalopathy (PML).
Raptiva (efalizumab) is a subcutaneous injection administered once a week to treat psoriasis. The drug is a therapeutic antibody designed to block the activation of special immune cells called T-cells. Overactivity of T-cells leads to excess skin cells being produced, which build up in the form of plaques, causing the skin disease psoriasis
The FDA approved Raptiva in October 2003, and it is manufactured and marketed by Genetech, Inc. Worldwide sales were approximately $120 million last year.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
On October 16, 2008, the FDA announced that a new Raptiva “black box” warning will be added to the drug’s label to highlight the risk of serious infections which could result from using the drug. This could include opportunistic infections such as bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy.
Progressive multifocal leukoencephalopathy or PML is a very serious brain infection which is often fatal. Although it is rare, the progressive disease causes inflammation and deterioration of the central nervous system and the brain, and there is no known cure.
The FDA also indicates that they are requiring the drug’s maker to develop a strategy for reducing the risk of infection among users and to distribute a Medication Guide to patients filling the prescription, which will further highlight the Raptiva infection side effects.
In a statement released by the FDA announcing the warnings, the agency indicated that individuals taking Raptiva should be educated about the signs of infection, PML, anemia, trombocytopenia or worsening of their psoriasis or arthritis. Symptoms could include confusion, dizziness, loss of balance, difficulty walking, difficulty taking, weakness, jaundice, bruising, bleeding gums, red or purple dots under the skin and vision problems.
ginaDecember 2, 2008 at 7:39 am
The second year i used raptiva I have noticed my skin to my face is loose and also to my fore arms I can pinch my skin its doesnt exspand b ack like anormal 40 my mother 70 and father 71 have better skin than i .
"*" indicates required fields
More Top Stories
A new report indicates the U.S. Navy is struggling to process tens of thousands of Camp Lejeune water poisoning claims due to a lack of resources.
A group of plaintiffs have filed a motion with the U.S. JPML seeking consolidation of all Bard implanted port lawsuits before one judge for pretrial proceedings.
A Tepezza hearing loss lawsuit accuses the manufacturer of failing to provide adequate warning about the risks of the thyroid eye disease drug.